Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avivagen Inc VIVXF

Avivagen Inc. is a Canada-based life sciences company. The Company is focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance. The Company’s operations as one segment, products based on OxC-beta Technology. It OxC-beta technology is derived from its discoveries about B-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colors. OxC- beta Livestock is a proprietary product, an alternative to the antibiotics commonly added to livestock feeds. The product is available for sale in the United States, Mexico, Philippines, Taiwan, New Zealand, Thailand, Australia and Malaysia. It offers OxC-beta to approximately 46.6 million food animals (poultry, swine, and dairy cattle), 133,820 dogs and 4,000 people.


GREY:VIVXF - Post by User

Post by DrJayseron Nov 01, 2022 9:28am
274 Views
Post# 35062526

Strong Corp- a 175,000$ Financing

Strong Corp- a 175,000$ Financing

Avivagen Inc. Announces Closing of Second Tranche of a Private Placement of Shares

OTTAWA, Ontario -- (Business Wire) --

Avivagen Inc. (TSXV:VIV) ("Avivagen" or the "Company"), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, announces that it has closed the second tranche (the "Second Tranche") of its previously announced non-brokered private placement financing (the "Offering")through the issuance of common shares of the Company (each, a "Common Share") at a price of $0.20 per Share (the "Offering Price") (for more information about the Offering and the first tranche thereunder, please see the Company's news release dated October 21, 2022 for more details.

The Company issued 875,000 Common Shares, for aggregate gross proceeds of $175,000 in the Second Tranche. In the aggregate of all two tranches of the Offering, the Company issued 3,025,000 Common Shares for gross proceeds of $605,000.


<< Previous
Bullboard Posts
Next >>